Avery Therapeutics

Avery Therapeutics is a private, pre-revenue biotech advancing a novel immunomodulatory platform for tissue regeneration, initially targeting heart failure with its lead candidate, MyCardia™. The company leverages strong scientific and medical advisory boards and is led by founder and CEO Jordan Lancaster, PhD. Operating in the high-value but challenging field of advanced tissue engineering, Avery aims to provide a restorative therapeutic option for a major unmet medical need in cardiovascular disease.

A novel immunomodulatory biologic platform that combines tissue engineering with immune system redirection to treat diseases of aging, inflammation, and fibrosis, aiming to restore organ function.

Avery operates in the competitive field of heart failure therapies and regenerative medicine, facing competition from large pharma's drug pipelines, device companies, and other biotechs developing cell/gene therapies. Its differentiation lies in its specific focus on immunomodulation within tissue engineering, a niche but potentially powerful approach.